DAP Stock Overview
Designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
DAP passed our risk checks.
Danaher Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$220.90 |
| 52 Week High | US$259.20 |
| 52 Week Low | US$198.20 |
| Beta | 0.88 |
| 11 Month Change | -9.11% |
| 3 Month Change | -8.26% |
| 1 Year Change | 8.50% |
| 33 Year Change | -21.81% |
| 5 Year Change | 66.04% |
| Change since IPO | 1,372.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| DAP | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -2.9% | -6.0% | -0.4% |
| 1Y | 8.5% | 1.4% | 7.1% |
Return vs Industry: DAP exceeded the German Life Sciences industry which returned 1.4% over the past year.
Return vs Market: DAP exceeded the German Market which returned 7.1% over the past year.
Price Volatility
| DAP volatility | |
|---|---|
| DAP Average Weekly Movement | 2.8% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DAP has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: DAP's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 62,000 | Rainer Blair | www.danaher.com |
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands.
Danaher Corporation Fundamentals Summary
| DAP fundamental statistics | |
|---|---|
| Market cap | €160.62b |
| Earnings (TTM) | €3.75b |
| Revenue (TTM) | €22.65b |
43.2x
P/E Ratio7.2x
P/S RatioIs DAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DAP income statement (TTM) | |
|---|---|
| Revenue | US$23.74b |
| Cost of Revenue | US$9.53b |
| Gross Profit | US$14.22b |
| Other Expenses | US$10.28b |
| Earnings | US$3.93b |
Last Reported Earnings
Sep 27, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.45 |
| Gross Margin | 59.87% |
| Net Profit Margin | 16.57% |
| Debt/Equity Ratio | 34.2% |
How did DAP perform over the long term?
See historical performance and comparison